N13 - Glomerular Diseases Flashcards

1
Q

Types of nephritis syndromes

A
  • acute nephritis syndrom
  • rapid progressive glomerulonephritis
  • chronic (asymptomatic) nephritis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Types of nephrosis syndrome

A

asympomatic urinary disorders: isolated hematuria, isolated proteinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Types of proteinuria

A
  • tubular proteinuria: low molecular weight proteins filtered through the glomerulus are not fully reabsorbed in the renal tubules
  • overflow proteinuria: overproduction of low molecular weight proteins
  • postrenal proteinuria: typically associated with UTI and leukocyturia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Proteinuria in nephrosis syndrome

A
  • protein in urine >3.5 g/day
  • serum albumin <3.5 g/dl
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Characteristics of acute nephritis syndrome

A
  • eGFR: decreases significantly in a few days
  • urine volume: oliguria
  • hematuria: microscopic or macroscopic, dysmorphic RBC, acanthrocytes, RBC cylinders
  • proteinuria: subnephrotic (typically 1-3g/day)
  • serum albumin: normal/slightly low
  • edema: generalized, caused by volume retention
  • blood pressure: can be high, very high
  • systemic symtoms: headache, anorexia

sudden onset, usually spontaneous improvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Characteristics of rapid progressive glomerulonephritis (RPGN) syndrome

A
  • eGFR: decreases significantly in a few days or 1-2 months
  • urine volume: can be oliguria
  • hematuria: mostly microscopic, dysmorphic RBC, acanthrocytes, RBC cylinders
  • proteinuria: subnephrotic (typically 1-3g/day)
  • serum albumin: normal/slightly low
  • edema: not typical but can be mild
  • blood pressure: not necessarily high
  • systemic symptoms: fever, weight loss, join pain, muscle pain, weakness, palpable purpura

sudden onset, rapid progression of uremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Characteristics of chronic (asymptomatic) nephritis

A
  • eGFR: can be maintained and decreases over years/decades
  • urine volume: normal
  • hematuria: mostly microscopic, sometimes macroscopic, dysmorphic RBC, acanthrocytes
  • proteinuria: subnephrotic (typically less than 3g/day)
  • serum albumin: mostly normal
  • blood pressure: often high
  • systemic symptoms: not characteristic

asymptomatic onset, slow progression of uremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

General treatment of nephritis syndromes

A
  • fluid status
  • reduce table salt intake (≤ 5g/day) and fluid intake (500-1000 mL/day)
  • furosemide: 40-160 mg/day (po. or iv.)
  • for dehydration: iv 0.9% NaCl infusion
  • regulation of blood pressure: ß-blocker, CCB, ACEi/ARB (↓eGFR) (infection control)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Characteristics of nephrosis syndrome

A
  • eGFR: normally maintained, but may decrease slowly with persistent and severe proteinuria
  • urine volume: normal
  • hematuria: not typical
  • proteinuria: nephrotic (>3g/day)
  • serum albumin: low
  • edema: pronounced (face + limbs)
  • blood pressure: normal or low systemic
  • systemic symptoms: not characteristic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Consequences of proteinuria in nephrosis syndrome

A
  • Generalized edema: oncotic pressure decreases so there is loss of tissue fluid and plasma volume decreases, leading to increased aldosterone levels and Na-retention
  • Hyperlipidemia: protein
  • Other possible effects:
    - venous thromboembolism due to ↓AT III
    - increased infection due to ↓IgG
    - osteomalacia due to ↓25(OH)D (calcediol)
    - ↓TBG, ↓T3 and T4
    - increased TSH (normal T3 and T4!!)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

General treatment of nephrotic syndromes

A
  • weight loss (0.5 - 1kg/day)
  • liquid and salt restriction (<5g/day)
  • furosemide 40 - 250 mg/day (po. or iv.)
    - +/- Hypothiazid 25 mg/Tag (po.)
    - +/- Aldosterone antagonist 25-100mg/day (po/iv.)
    - 20% albumin, 100mL
  • proteinuria reducing
    - ACEi/ARB
    - blood pressure ≤ 125/75 Hgmm
    - 0.8 g/kg/day protein restriction
  • anticoagulant treatment
    - ASA
    - when serum albumin <20 g/L : LMWH!!
  • lipid lowering drugs:
    - normal kidney function in addition to fibrates, otherwise statins (infection control)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Serum investigaion of glomerulopathies

A
  • creatinine
  • urea
  • ions
  • albumin
  • CRP
  • AST
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Immunoglobulin investigation of glomerulopathies

A

IgA, IgG, IgM, cryoglobulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Complement investigation of glomerulopathies

A

C3, C4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Serum light chain investigation of glomerulopathies

A
  • Serum ELFO
  • λ
  • κ
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antibodies investigation of glomerulopathies

A
  • ANA
  • anti-dsDNA
  • ANCA
  • antiPLA2R
  • antiC1q
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Histological investigation of glomerulopathies

A

blood count, hand swab, reticulocytes

17
Q

Protein excretion investigation of glomerulopathies

A
  • in mg/24h or mg/mmol
  • albumin/creatinine or total protein/creatinine
18
Q

Urine investigation of glomerulopathies

A
  • urine sediment test
  • Stix
  • protein ELFO
19
Q

Microbiological investigation of glomerulopathies

A
  • culture tests: urine, stool, respiratory secretions, or hemoculture
  • serological tests
  • bacterial or viral detection
20
Q

Imaging for glomerulopathies

A
  • chest Rtg
  • abdominal ultrasound (kidney size, parenchyma)
21
Q

Types of proliferation in proliferative glomerular diseases

A
  • endocapillary: endothelial cells
  • mesangio capillary: mesangial and endothelial cells
  • mesangial: mesangial cells
  • extracapillary: podocytes and parietal epithelial cells
22
Q

Characteristics of ANCA vasulitis

A
  • rapidly progressing glomerulonephritis; proliferative
  • special labs: increase anti-MPO or anti-PR3, possibly eosinophilia, normal complement values
  • relatively common disease in middle-aged/elderly patients
  • consequences: pulmonary-kidney syndrome, symptoms of upper resp. tract (GPA), asthma, chronic rhinorrhea (EGPA), purpura, necrotizing vasculitis on skin

Histology
LM: extracapillary proliferation w/ crescent formation
IF: pauci-immune
EM: basement membrane rupture, no immune complex

23
Q

Characteristics of goodpasture syndrome

A
  • rapidly progressing glomerulonephritis; proliferation
  • special labs: increased anti-GBM, possible ANCA positivity, normal complement values
  • extremely rare disease
  • lung and kidney syndrome, no systemic symptoms

Histology
- LM: extracapillary proliferation w/ crescent formation
- IF: linear IgG deposition
- EM: basement membrane rupture

24
Q

Characteristics of SLE nephritis

A
  • can be any nephritis syndrome
  • proliferative or basement membrane damage or both
  • special labs: ANA-screen positive, elevated anti-dsDNA and anti-C1q, decreased C3 and C4, possibly accompanied by pancytopenia
  • young or middle age patients
  • other symptoms: skin, mucous membranes, serous membranes of nervous system, heart etc.

Histology
- LM: mild mesangial proliferation; or endocapillary proliferation ± crescent formation; or basement membrane thickening
- IF: grainy IgG, A, M, C3, C1q (“full house”!!)
- EM: subendothelial electron-dense deposits

25
Q

Characteristics of IgA nephropathy

A
  • 50% isolated macroscopic hematuria; 40% chronic nephritis
  • proliferative
  • special labs: increased IgA, normal complement values (essentially negative lab results)
  • common disease of youth
  • symptoms: hematuria w/ upper resp. tract infection; screened patient (hematuria + proteinuria + hypertension) sometimes with very low eGFR

Histology
- LM: mesangial hypercellularity
- IF: granular IgA, C3, C5b-9
- EM: mesangial electron-dense deposits

26
Q

Characteristics of Schönlein-Enoch Purpura

A
  • 80% nephritis with systemic symptoms; 20% nephroso-nephritis
  • proliferative
  • special labs: possibly increased IgA; normal complement values (essentially negative lab results)
  • young patients (90% child)
  • symptoms: palpable purpura + no thrombopenia/coagulopathy; joint pain; abdominal pain; bleeding in lower GI; hematuria/deteriorating eGFR

Histology
- IgA is indistinguishable from nephropathy

27
Q

Characteristics of membranoproliferative/mesangiocapillaris glomerulonephritis

A
  • most often nephroso-nephritis of nephrosis syndrome, but can be anything
  • proliferative and non-proliferative (mixed)
  • special labs: ↑cryoglobulin
    - immune complex-mediated MCGN: low C4 + normal C3
    - complement-mediated MCGN: low C3 + normal C4
  • rare disease, heterogenous etiology

Histology
- mesangial and endocapillary proliferation
- thickening/doubling of the basement membrane
-IF: granular deposition
- EM: subendothelial immune complexes, double basement membrane

28
Q

Characteristics of minimal change disease

A
  • nephrosis syndrome
  • non-proliferative
  • special labs: none
  • often in childhood, the second form can occur in Hodgkin’s disease

Histology
- not required in childhood; excellent response to corticosteroid therapy
- FM: normal
- IF: negative
- EM: merging of podocyte foot extensions

29
Q

Characteristics of focal segmental glomerulosclerosis

A
  • nephrotic syndrome ± decreasing GFR
  • non-proliferative
  • special labs: none
  • more common in black people
  • second form can be: HIV, heroine abuse, extremely low birth weight, extreme obesity, bodybuilding, obstructive uropathy

Histology
- FM: ECM accumulation, collapsed capillaries, capillary adhesion near intact glomeruli (focal) and glomerular parts (segmental)
- IF: IgM and C3 positivity
- EM: confluence of podocyte foot extensions, crumpled basement membrane, subendothelial hyaline

30
Q

Characteristics of membranous nephropathy

A
  • nephrosis syndrome
  • non-proliferative
  • special labs: positivity of the anti-phospholipase A2 receptor (PLA2R) in 70% of primary form
  • more common in the elderly
  • thrombosis is a common complication
  • second form can be: solid tumor, chronic infection, autoimmune disease

Histology
- FM: thickening of the basement membrane with tip-like protrusions
- IF: granular deposition of IgG4 and C3
- EM: subepithelial electron-dense deposits

31
Q

Characteristics of diabetic nephropathy

A
  • nephrotic syndrome/isolated proteinuria ± decreasing GFR
  • non-proliferative
  • special labs: none, persistently high HbA1c for long time
  • usually due to a long-term, undertreated DM
  • retinopathy also exists with T1DM, not necessarily with T2DM
  • kidneys checked with abdominal ultrasound; slow progression

Histology
- FM: mesangial expansion, nodular glomerulosclerosis (Kimmelstiel-Wilson syndrome)
- IF: no typical deviation
- EM: basement membrane thickening, podocyte death, mesangial expansion

32
Q

Characteristics of amyloidosis

A
  • nephrotic syndrome ± decreasing GFR
  • non-proliferative abnormalities
  • special labs: may contain monoclonal protein in serum/urine (electrophoresis + immunofixation)
  • rare disese, elderly patients
  • enlarged kidneys with abdominal ultrasound, organomegaly, purpura

Histology
- increased risk of bleeding
- FM: mesangial expansion, nodular glomerulosclerosis; congo staining (painted red in light apple green birefringence)
- IF: AL for amyloid kappa or lambda positivity
- EM: fibrils in the mesangium

33
Q

Treatment options for acute nephritis

A

Poststreptococcal GN (supportive therapy)
- volume and salt absorption control
- loop diuretic (furosemide 1x40mg)
- antihypertensive therapy (CCB, ACE inhibitors or ARB only with caution)
- renal replacement therapy

34
Q

Treatment options for chronic nephritis

A

IgA nephropathy:
- antihypertensive and anti-proteinuria therapy (ACE inhibitors/ARB)
- fish oil
- depending on the tissue p.o. steroid (for 1/2 year, gradually downwards)

35
Q

Treatment options for rapid progressive glomerulonephritis

A

SLE nephritis / goodpasture syndrome / ANCA vasculitis
- aggressive immunosuppression is required
- induction (3-6 months): iv. then po. steroid + cyclophosphamide/rituximab/MMF
- plasmapheresis
- maintenace therapy (1-2 years): azathioprine, MMF, rituximab, or methotrexate

36
Q

Treatment options for minimal change

A
  • usually a good response to steroids
  • cyclosporine if steroid dependence or steroid resistance occurs
37
Q

Treatment options for focal segmental glomerulosclerosis

A
  • longer-term steroid therapy is required
  • cyclosporine or MMF is common in case of steroid resistance/dependence
38
Q

Treatment options for membranous nephropathy

A
  • steroid + cyclophosphamide/cyclosporine
  • rituximab in case of therapy resistance
  • spontaneour remission may occur
39
Q

Treatment options for diabetic nephropathy

A
  • adequate blood sugar control
  • ACE inhibitors or ARB to control blood pressure and reduce proteinuria
  • reduction of salt intake
40
Q

Treatment options for amyloid

A

hematological treatment